Business Standard
Thursday, May 31, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Ranbaxy, Aurobindo get USFDA nod for migraine drug
BS Reporter / Mumbai Aug 11, 2009, 15:17 IST

Pharma majors Ranbaxy and Aurobindo Pharma today said that they have received final approval from the US Food and Drug Administration(USFDA) to manufacture and market Sumatripan Succinate.

While Ranbaxy got approval for 25 and 50 mg varients of the drug, Aurobindo got the approval for 100 mg tablets apart from 25 and 50 mg tablets.

The Office of Generic Drugs, USFDA, has determined the Ranbaxy formulations to be bio-equivalent and have the same therapeutic effect that of the reference listed drug Imitrex manufactured by GlaxoSmithkilne.

The drug is used in the treatment of migraine in adults. Ranbaxy shares were trading at Rs 275.25, nearly 14.25 per cent higher than Monday's close. Aurobindo stock was trading at Rs 615.05, nearly 3.35 per cent down from Monday's close.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets languish as heavyweights drag
- Silver futures down 0.5% on global cues, weak spot demand
- Gold futures down on global cues, sluggish spot demand
- Manmohan govt must seek fresh mandate: Sharad Yadav
- Nickel gains 0.31% as demand picks up
  Read Business news in 
- India's no. 1 Property Site. Click here to know more
- "Discover The Power of One"
- Help a Child Achieve her. Click to know more
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Learn How One City is Running on FOOD SCRAPS.
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
- 2 Lac Apartments, 1 Lac House / Plots. Click here
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- NDA-led bandh turns violent in Bangalore
- Investors wary as Flipkart shows growth pangs
- Army chief slams BEML on Tatra, awards it Rs 1,500-cr deal
- Wealthy clients turned tables on UBS and staff?
- Kingfisher Airlines Q4 loss more than trebles
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us